OCUGEN, INC. Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
OCUGEN, INC. (OCGN) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2026-03-04
- OCUGEN, INC. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2025 was $0.00.
- OCUGEN, INC. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2024 was $0.00.
- OCUGEN, INC. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2023 was $0.00.
- OCUGEN, INC. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2022 was $0.00.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-04 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-04 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-05 |
| 2022-12-31 | $0.00 10-K · filed 2024-04-16 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-28 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-28 |
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |